Stempoint Capital LP Reduces Stock Holdings in Celcuity, Inc. $CELC

Stempoint Capital LP trimmed its position in shares of Celcuity, Inc. (NASDAQ:CELC) by 49.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,062 shares of the company’s stock after selling 58,271 shares during the period. Celcuity accounts for approximately 1.3% of Stempoint Capital LP’s portfolio, making the stock its 28th largest holding. Stempoint Capital LP’s holdings in Celcuity were worth $6,855,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of CELC. Janus Henderson Group PLC raised its stake in shares of Celcuity by 54.8% in the first quarter. Janus Henderson Group PLC now owns 9,600 shares of the company’s stock valued at $1,095,000 after buying an additional 3,400 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Celcuity by 139.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 820 shares of the company’s stock worth $94,000 after acquiring an additional 477 shares during the period. California State Teachers Retirement System grew its stake in shares of Celcuity by 91.2% during the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after acquiring an additional 12,201 shares during the period. Royal Bank of Canada grew its stake in shares of Celcuity by 12.9% during the 1st quarter. Royal Bank of Canada now owns 7,866 shares of the company’s stock worth $898,000 after acquiring an additional 901 shares during the period. Finally, Quantinno Capital Management LP increased its holdings in Celcuity by 7.7% in the 1st quarter. Quantinno Capital Management LP now owns 22,161 shares of the company’s stock worth $2,529,000 after acquiring an additional 1,583 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. This represents a 27.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by corporate insiders.

Celcuity Stock Performance

Shares of CELC opened at $83.21 on Thursday. The company has a market cap of $4.06 billion, a PE ratio of -21.34 and a beta of 0.16. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock has a 50-day moving average price of $100.93 and a 200-day moving average price of $109.92. Celcuity, Inc. has a 12-month low of $38.00 and a 12-month high of $151.02.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities analysts forecast that Celcuity, Inc. will post -3.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus set a $150.00 price objective on Celcuity in a research note on Monday, May 4th. Citigroup reiterated an “outperform” rating on shares of Celcuity in a research report on Wednesday, July 15th. Leerink Partners set a $155.00 target price on shares of Celcuity in a research note on Tuesday, June 2nd. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Finally, Guggenheim restated a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $155.18.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.